| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndrome (MDS) and Failure of Therapy with Hypomethylating Agents (HMA): An Emerging Entity With a Poor Prognosis
|
Ghanem, Hady
|
|
2013
|
13 |
S2 |
p. S379-
1 p.
|
artikel
|
| 2 |
Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes
|
Oran, Betul
|
|
2013
|
13 |
S2 |
p. S282-S288
7 p.
|
artikel
|
| 3 |
Allogeneic Stem Cell Transplantation and Targeted Immunotherapy for Multiple Myeloma
|
Danylesko, Ivetta
|
|
2013
|
13 |
S2 |
p. S330-S348
19 p.
|
artikel
|
| 4 |
Antagonizing IAPs by SMAC Mimetic Birinapant Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination With Chemotherapy in vitro and in vivo
|
Carter, Bing Z.
|
|
2013
|
13 |
S2 |
p. S376-S377
2 p.
|
artikel
|
| 5 |
A Phase I/II Trial of Combination of PKC412 and 5-azacytidine (AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
|
Nazha, Aziz
|
|
2013
|
13 |
S2 |
p. S374-S375
2 p.
|
artikel
|
| 6 |
A Phase I Trial of Lenalidomide in Combination with Intermediate Dose Cytarabine (IDC) in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients
|
Vigil, Carlos E.
|
|
2013
|
13 |
S2 |
p. S380-
1 p.
|
artikel
|
| 7 |
ARC Is Regulated by MAPK and PI3K and Confers Drug Resistance and Survival Advantage to AML in vitro and in vivo
|
Mak, Po Yee
|
|
2013
|
13 |
S2 |
p. S376-
1 p.
|
artikel
|
| 8 |
Are All Interferons the Same for Therapy in Polycythemia Vera?
|
Silver, Richard T.
|
|
2013
|
13 |
S2 |
p. S305-S306
2 p.
|
artikel
|
| 9 |
Biological and Clinical Features of Trisomy 21 Acute Myeloid Leukemia
|
Strati, Paolo
|
|
2013
|
13 |
S2 |
p. S375-S376
2 p.
|
artikel
|
| 10 |
Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia
|
Strati, Paolo
|
|
2013
|
13 |
S2 |
p. S276-S281
6 p.
|
artikel
|
| 11 |
Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma
|
Cervantes-Gomez, Fabiola
|
|
2013
|
13 |
S2 |
p. S317-S329
13 p.
|
artikel
|
| 12 |
Characteristics, Response to Therapy and Outcome of African American Patients With Chronic Lymphocytic Leukemia
|
Falchi, Lorenzo
|
|
2013
|
13 |
S2 |
p. S363-S364
2 p.
|
artikel
|
| 13 |
Chronic Myeloid Leukemia Philadelphia Chromosome Positive (CML Ph+) With Imatinib (IM) Intolerance or Resistant Disease - Response to Thalidomide (TALI) Treatment - Preliminary Report of a Serial of Cases With Encouraging Results
|
Hurtado-Monroy, Rafael
|
|
2013
|
13 |
S2 |
p. S385-S386
2 p.
|
artikel
|
| 14 |
Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Personalize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Shum, David
|
|
2013
|
13 |
S2 |
p. S378-
1 p.
|
artikel
|
| 15 |
Clinical Implication of Discrepancy in the Diagnosis of Primary Myelofibrosis between Referral and Tertiary Center
|
Yi, Cecilia Arana
|
|
2013
|
13 |
S2 |
p. S372-S373
2 p.
|
artikel
|
| 16 |
Combination of Pim Kinase Inhibitor SGI-1776 and Bendamustine in B-Cell Lymphoma
|
Yang, Qingshan
|
|
2013
|
13 |
S2 |
p. S355-S362
8 p.
|
artikel
|
| 17 |
Comparison of Outcome in Erythroleukemia Patients Treated with Standard Chemotherapy Regimens or Hypomethylating Agents
|
Vigil, Carlos E.
|
|
2013
|
13 |
S2 |
p. S380-S381
2 p.
|
artikel
|
| 18 |
Continuing Medical Education Post-Test[Course Code: MEMV 1116]
|
|
|
2013
|
13 |
S2 |
p. S387-S390
4 p.
|
artikel
|
| 19 |
Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome
|
Ghanem, Hady
|
|
2013
|
13 |
S2 |
p. S289-S294
6 p.
|
artikel
|
| 20 |
Deletion 11q Abnormality in Patients With Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (Clinical and Radiological) at Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients With CLL and del11q Cytogenetic Abnormality
|
Jain, Preetesh
|
|
2013
|
13 |
S2 |
p. S365-
1 p.
|
artikel
|
| 21 |
Editorial Board/Masthead
|
|
|
2013
|
13 |
S2 |
p. A6-
1 p.
|
artikel
|
| 22 |
HCVAD plus Imatinib or Dasatinib for Lymphoid Blastic Phase of Chronic Myeloid Leukemia
|
Strati, Paolo
|
|
2013
|
13 |
S2 |
p. S384-S385
2 p.
|
artikel
|
| 23 |
High-Throughput Sequencing to Detect Minimal Residual Disease in Acute T Lymphoblastic Leukemia
|
Sherwood, Anna
|
|
2013
|
13 |
S2 |
p. S369-
1 p.
|
artikel
|
| 24 |
Hypoxia Activated Pro-Drug TH-302 Induces Hypoxia-Dependent Anti-leukemia Activity in vitro and in vivo
|
Benito, Juliana M.
|
|
2013
|
13 |
S2 |
p. S377-
1 p.
|
artikel
|
| 25 |
In vitro Effect of AZD1208 (Pim Kinase Inhibitor) and 17-AAG (HSP90 Inhibitor) Combination in CLL
|
Cervantes-Gomez, Fabiola
|
|
2013
|
13 |
S2 |
p. S366-
1 p.
|
artikel
|
| 26 |
Long Term Effect of Decitabine (DAC) Dose Delay (DD) and Dose Reduction (DR) on Survival and Progression of Patients (pts) with Myelodysplastic Syndrome (MDS)
|
Ghanem, Hady
|
|
2013
|
13 |
S2 |
p. S374-
1 p.
|
artikel
|
| 27 |
Management of Cytopenias With Ruxolitinib Treatment in Patients With Myelofibrosis
|
Verstovsek, Srdan
|
|
2013
|
13 |
S2 |
p. S371-
1 p.
|
artikel
|
| 28 |
Mutant NPM1 is a Reliable Marker of Minimal Residual Leukemia in Patients with Acute Myeloid Leukemia
|
Jain, Preetesh
|
|
2013
|
13 |
S2 |
p. S378-S379
2 p.
|
artikel
|
| 29 |
Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study
|
Xu-Monette, Zijun Y.
|
|
2013
|
13 |
S2 |
p. S382-
1 p.
|
artikel
|
| 30 |
MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study
|
Hu, Shimin
|
|
2013
|
13 |
S2 |
p. S382-S383
2 p.
|
artikel
|
| 31 |
Novel Caspase-3 Activator, L14R8, Induces Apoptosis in CLL cells
|
Patel, ViralKumar
|
|
2013
|
13 |
S2 |
p. S366-S367
2 p.
|
artikel
|
| 32 |
Novel Treatment Options for Waldenström Macroglobulinemia
|
Leblebjian, Houry
|
|
2013
|
13 |
S2 |
p. S310-S316
7 p.
|
artikel
|
| 33 |
Other Cancers in Patients With Chronic Lymphocytic Leukemia Requiring Therapy: Association With Prognostic Factors and Impact on Survival
|
Falchi, Lorenzo
|
|
2013
|
13 |
S2 |
p. S364-
1 p.
|
artikel
|
| 34 |
PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation
|
Cortes, Jorge E.
|
|
2013
|
13 |
S2 |
p. S384-
1 p.
|
artikel
|
| 35 |
Phase II Study of Nelarabine With Hyper-CVAD in Patients With Previously Untreated T cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)
|
Jain, Preetesh
|
|
2013
|
13 |
S2 |
p. S368-S369
2 p.
|
artikel
|
| 36 |
Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia
|
Jacoby, Meagan A.
|
|
2013
|
13 |
S2 |
p. S374-
1 p.
|
artikel
|
| 37 |
Phosphorylation of GSK3β is Prognostic for Inferior Survival in Acute Myeloid Leukemia
|
Ruvolo, Peter
|
|
2013
|
13 |
S2 |
p. S375-
1 p.
|
artikel
|
| 38 |
Prognostic Factors and Risk Models in Myelodysplastic Syndromes
|
Komrokji, Rami S.
|
|
2013
|
13 |
S2 |
p. S295-S299
5 p.
|
artikel
|
| 39 |
Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms
|
Bartalucci, Niccolò
|
|
2013
|
13 |
S2 |
p. S307-S309
3 p.
|
artikel
|
| 40 |
Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) on Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) With Acute Promyelocytic Leukemia (APL) Treated With All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO)
|
Ghanem, H.
|
|
2013
|
13 |
S2 |
p. S377-S378
2 p.
|
artikel
|
| 41 |
Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)
|
Takahashi, Koichi
|
|
2013
|
13 |
S2 |
p. S373-
1 p.
|
artikel
|
| 42 |
Relationship Between Ruxolitinib Dose and Improvements in Spleen Volume and Symptoms in Patients With Myelofibrosis: Results From COMFORT-I
|
Mesa, Ruben A.
|
|
2013
|
13 |
S2 |
p. S371-S372
2 p.
|
artikel
|
| 43 |
Retrospect of Hematological Malignancies 2012
|
Freireich, Emil J.
|
|
2013
|
13 |
S2 |
p. S271-
1 p.
|
artikel
|
| 44 |
Role of Consolidation/Maintenance Therapy in Multiple Myeloma
|
Palumbo, Antonio
|
|
2013
|
13 |
S2 |
p. S349-S354
6 p.
|
artikel
|
| 45 |
Second Cancers (SC) Affect the Clinical Outcome of Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Frontline FCR Therapy
|
Benjamini, Ohad
|
|
2013
|
13 |
S2 |
p. S365-S366
2 p.
|
artikel
|
| 46 |
Second Generation TKIs Can Induce Complete Molecular Response in Ph-Positive Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplant
|
Fava, C.
|
|
2013
|
13 |
S2 |
p. S367-S368
2 p.
|
artikel
|
| 47 |
Second-Generation Tyrosine Kinase Inhibitors Can Induce Complete Molecular Response in Ph-Positive Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplant
|
Fava, Carmen
|
|
2013
|
13 |
S2 |
p. S272-S275
4 p.
|
artikel
|
| 48 |
Signal Transducer and Activator of Transcription (STAT)-3 Activates Nuclear Factor (NF)-κB in Primary Myelofibrosis (PMF) Bone Marrow Cells
|
Grgurevic, Srdana
|
|
2013
|
13 |
S2 |
p. S370-S371
2 p.
|
artikel
|
| 49 |
Signal Transducer and Activator of Transcription (STAT)-3-Dependent Regulation of Non-Coding RNA in Small lymphocytic lymphoma/Chronic lymphocytic leukemia (CLL)
|
Rozovski, Uri
|
|
2013
|
13 |
S2 |
p. S363-
1 p.
|
artikel
|
| 50 |
Successful Long-Term Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms With Combination of Hydroxyurea and Anagrelide
|
Ahn, Inhye E.
|
|
2013
|
13 |
S2 |
p. S370-
1 p.
|
artikel
|
| 51 |
Successful Long-Term Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms With Combination of Hydroxyurea and Anagrelide
|
Ahn, Inhye E.
|
|
2013
|
13 |
S2 |
p. S300-S304
5 p.
|
artikel
|
| 52 |
Table of Contents
|
|
|
2013
|
13 |
S2 |
p. A7-A8
nvt p.
|
artikel
|
| 53 |
Targeted Alpha-particle Nano-generator Actinium-225 (225Ac)-lintuzumab (anti-CD33) in Acute Myeloid Leukemia (AML)
|
Jurcic, J.G.
|
|
2013
|
13 |
S2 |
p. S379-S380
2 p.
|
artikel
|
| 54 |
Targeting the Pro-Survival Protein c-MET With ARQ 197 Inhibits Growth of Multiple Myeloma Cells
|
Zaman, Shadia
|
|
2013
|
13 |
S2 |
p. S381-
1 p.
|
artikel
|
| 55 |
The hsa-let-7a miRNA Enhances Ara-C Induced Apoptosis in Human Acute Myeloid Leukemia Cells
|
Chen, Ye
|
|
2013
|
13 |
S2 |
p. S368-
1 p.
|
artikel
|
| 56 |
The Pro-apoptotic Effect of Kefir in Malignant T-lymphocytes Involves a p53 Dependent Pathway
|
Rizk, Sandra
|
|
2013
|
13 |
S2 |
p. S367-
1 p.
|
artikel
|
| 57 |
Transcription and Translation are Primary Targets of Pim Kinase Inhibitor SGI-1776 in Mantle Cell Lymphoma
|
Yang, Qingshan
|
|
2013
|
13 |
S2 |
p. S383-
1 p.
|
artikel
|
Tijdschrift beschrijving